Draft Guidance on Candesartan Cilexetil; Hydrochlorothiazide

This draft guidance, once finalized, will represent the Food and Drug Administration's (FDA's) current thinking on this topic. It does not create or confer any rights for or on any person and does not operate to bind FDA or the public. You can use an alternative approach if the approach satisfies the requirements of the applicable statutes and regulations. If you want to discuss an alternative approach, contact the Office of Generic Drugs.

**Active Ingredient:** Candesartan Cilexetil; Hydrochlorothiazide

**Form/Route:** Tablets/Oral

**Recommended Studies:** 2 studies

1. **Type of study:** Fasting  
   **Design:** Single-dose, two-way crossover *in-vivo*  
   **Strength:** 32 mg/25 mg  
   **Subjects:** Normal, healthy, males and females, general population  
   **Additional comments:** Female subjects should be excluded from the bioequivalence studies if they are pregnant.

2. **Type of study:** Fed  
   **Design:** Single-dose, two-way crossover *in-vivo*  
   **Strength:** 32 mg/25 mg  
   **Subjects:** Normal, healthy, males and females, general population  
   **Additional comments:** Female subjects should be excluded from the bioequivalence studies if they are pregnant.

**Analytes to measure (in appropriate biological fluid):** Candesartan and hydrochlorothiazide in plasma.

**Bioequivalence based on (90% CI):** Candesartan and hydrochlorothiazide

**Requests of Waivers of in-vivo Testing:** 16 mg/12.5 mg and 32 mg/12.5 mg based on (i) acceptable bioequivalence studies on the 32 mg/25 mg strength, (ii) formulation proportionality across all strengths, and (iii) acceptable in vitro dissolution testing of all strengths.

**Dissolution test method and sampling times:**

Please note that a Dissolution Methods Database is available to the public at the OGD website at [http://www.fda.gov/cder/ogd/index.htm](http://www.fda.gov/cder/ogd/index.htm). Please find the dissolution information for this product at this website. Please conduct comparative dissolution testing on 12 dosage units each of all strengths of the test and reference products. Specifications will be determined upon review of the application.

*Recommended Aug 2004, Sept 2008*